Clinical Trial Information Request for Protocol 25-273 Title A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION, AND DOSE-OPTIMIZATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND ACTIVITY OF EIK1004 (IMP1707) AS MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS. PI Site Directions: Type your name, contact email and phone number (optional) into the boxes below then click Save to Submit your request for information about this study. Name Email Phone